Subscribe to our newsletter to receive the latest product updates and special offers

HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite
Theme 		Help
Order by Signal Tickers
Filters
Overview Valuation Financial Ownership Performance Technical ETF ETF Perf Custom Charts Tickers Basic TA News Snapshot Maps Stats
#51 / 200 Total
CHRO - Chromocell Therapeutics Corp. - Stock Price Chart
TickerCHRO [AMEX]
CompanyChromocell Therapeutics Corp.
CountryUSA
IndustryBiotechnology
Market Cap8.42MEPS (ttm)-1.54
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B7.45EPS Q/Q-165.10%
Dividend-Sales Q/Q-
Insider Own79.53%Inst Own9.90%
Insider Trans0.00%Inst Trans-
Short Float0.31%EarningsMay 29
Analyst Recom1.00Target Price8.50
Avg Volume19.33K52W Range1.06 - 6.00
Jul-15-24 09:00AM Chromocell to Participate in the Virtual Investor Lunch Break Series (GlobeNewswire)
May-13-24 09:00AM Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024 (GlobeNewswire) +38.25%
Apr-09-24 08:30AM Chromocell Issues Letter to Stockholders from Chief Executive Officer (GlobeNewswire) -8.37%
Mar-21-24 08:30AM Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler (GlobeNewswire)
Mar-18-24 10:00AM Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023 (GlobeNewswire) -5.44%
Mar-12-24 10:30AM Sidoti Events, LLC's Virtual March Small-Cap Conference (ACCESSWIRE)
Mar-11-24 09:00AM Chromocell to Present at Sidoti Virtual Investor Conference March 13-14 (GlobeNewswire) -6.31%
Feb-27-24 08:00AM Benuvia Operations, LLC and Chromocell Therapeutics Corp. Announce Strategic Partnership to Advance Healthcare Solutions (GlobeNewswire)
Feb-21-24 04:47PM Chromocell Therapeutics Announces Closing of Initial Public Offering for Gross Proceeds of $6.6 Million (GlobeNewswire)
Feb-16-24 08:00AM Chromocell Therapeutics Announces Pricing of Upsized $6.6 Initial Public Offering (GlobeNewswire)
MYSZ - My Size Inc - Stock Price Chart
TickerMYSZ [NASD]
CompanyMy Size Inc
CountryIsrael
IndustrySoftware - Application
Market Cap1.83MEPS (ttm)-25.72
P/E-EPS this Y62.75%
Forward P/E-EPS next Y-
PEG-EPS past 5Y49.60%
P/S0.20EPS next 5Y-
P/B0.06EPS Q/Q-12.38%
Dividend-Sales Q/Q314.44%
Insider Own14.93%Inst Own0.96%
Insider Trans0.00%Inst Trans-
Short Float1.83%EarningsMay 16/b
Analyst Recom1.00Target Price5.00
Avg Volume93.84K52W Range2.35 - 21.92
Jun-19-24 06:00AM 3 52-Week-Low Losers Ready to Become Big-Time Stock Winners (InvestorPlace)
Jun-11-24 09:55AM My Size (MYSZ) Forms 'Hammer Chart Pattern': Time for Bottom Fishing? (Zacks)
May-16-24 09:00AM MySize Reports First Quarter 2024 Financial Results: Record Three-Month Revenues and Gross Profits (PR Newswire)
May-07-24 10:08AM My Size Regains Compliance with Nasdaq Minimum Closing Bid Price Rule (PR Newswire) -6.69%
Apr-15-24 04:15PM My Size Announces Reverse Stock Split (PR Newswire) +11.12%
Apr-02-24 09:52AM MYSZ Stock Earnings: My Size Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
Feb-22-24 09:00AM Naiz Fit, a My Size Inc Company, Unveils Groundbreaking Generative AI Strategies to Revolutionize Fashion Tech (PR Newswire)
Jan-11-24 09:00AM MySize to Exhibit at National Retail Federation 2024 in New York City (PR Newswire) -6.05%
Dec-05-23 09:00AM Fox Business Network TV show, Varney and Company Interviews MySize CEO Ronen Luzon (PR Newswire)
Nov-15-23 09:00AM MySize Reports Third Quarter 2023 Financial Results: Record Nine-Month Revenues and Gross Profits (PR Newswire)
AVGR - Avinger Inc - Stock Price Chart
TickerAVGR [NASD]
CompanyAvinger Inc
CountryUSA
IndustryMedical Instruments & Supplies
Market Cap2.88MEPS (ttm)-19.48
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y70.26%
P/S0.38EPS next 5Y-
P/B-EPS Q/Q64.67%
Dividend-Sales Q/Q-1.54%
Insider Own29.97%Inst Own1.54%
Insider Trans0.00%Inst Trans-
Short Float2.47%EarningsMay 15/a
Analyst Recom1.00Target Price5.00
Avg Volume18.54K52W Range1.59 - 14.00
Today 07:36AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday (InvestorPlace) -11.80%
Jun-17-24 04:05PM Avinger Announces Closing of up to $24 Million Public Offering (ACCESSWIRE) +5.08%
Jun-14-24 08:00AM Avinger Announces Pricing of up to $24 Million Public Offering (ACCESSWIRE)
Jun-05-24 07:30AM Avinger Increases Focus on Coronary Development, Reduces Operating Costs of Peripheral Business (ACCESSWIRE) +7.41%
May-17-24 09:40AM Are Medical Stocks Lagging Avinger (AVGR) This Year? (Zacks)
May-16-24 04:05PM Avinger Announces Conversion of $11 Million of CRG Debt into Preferred Equity (ACCESSWIRE)
11:01AM Avinger Inc (AVGR) Q1 2024 Earnings Call Transcript Highlights: Strategic Partnerships and ... (GuruFocus.com)
May-15-24 08:54PM AVGR Stock Earnings: Avinger Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:26PM Avinger: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM Avinger Reports First Quarter 2024 Results (ACCESSWIRE)
ICU - SeaStar Medical Holding Corp - Stock Price Chart
TickerICU [NASD]
CompanySeaStar Medical Holding Corp
CountryUSA
IndustryBiotechnology
Market Cap36.70MEPS (ttm)-25.32
P/E-EPS this Y71.24%
Forward P/E-EPS next Y73.10%
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q53.16%
Dividend-Sales Q/Q-
Insider Own11.46%Inst Own4.15%
Insider Trans0.00%Inst Trans-2.26%
Short Float3.30%EarningsMay 14/a
Analyst Recom1.00Target Price18.00
Avg Volume307.98K52W Range3.25 - 42.92
Today 09:00AM Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's QUELIMMUNE Therapy at Cincinnati Children's (GlobeNewswire) +11.53%
Jul-23-24 08:30AM First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical's FDA-Approved QUELIMMUNE Therapeutic Device (GlobeNewswire) +9.78%
Jul-17-24 09:00AM Nuwellis Marks First Commercial Sale of QUELIMMUNE Therapy to Cincinnati Children's (GlobeNewswire)
Jul-16-24 08:30AM CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical's Selective Cytopheretic Device Pivotal Trial (GlobeNewswire) +6.71%
Jul-12-24 08:30AM SeaStar Medical Ships First QUELIMMUNE Product Order to U.S. Distribution Partner (GlobeNewswire) +12.27%
Jul-11-24 04:05PM SeaStar Medical Announces Closing of $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -5.08%
Jul-10-24 09:00AM SeaStar Medical Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -37.92%
Jul-03-24 08:30AM SeaStar Medical Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device (GlobeNewswire)
Jun-12-24 07:00AM Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now (GlobeNewswire) -10.53%
Jun-11-24 08:30AM SeaStar Medical's Selective Cytopheretic Device Featured in Two Presentations at the 42nd Vicenza Course AKI-CRT-ECOS and Critical Care Nephrology (GlobeNewswire)
OCEA - Ocean Biomedical Inc. - Stock Price Chart
TickerOCEA [NASD]
CompanyOcean Biomedical Inc.
CountryUSA
IndustryBiotechnology
Market Cap44.35MEPS (ttm)-3.83
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S-EPS next 5Y-
P/B-EPS Q/Q-587.66%
Dividend-Sales Q/Q-
Insider Own73.62%Inst Own13.06%
Insider Trans0.00%Inst Trans2.64%
Short Float2.37%Earnings-
Analyst Recom1.00Target Price18.50
Avg Volume223.83K52W Range0.52 - 7.79
Jun-12-24 07:46AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday (InvestorPlace) -10.00%
Jun-05-24 07:01AM Ocean Biomedical (NASDAQ: OCEA) Congratulates Joint Venture Partner, Virion Therapeutics, on Positive Immunogenicity Results from Their Lead Checkpoint Modifier-Containing Immunotherapy, VRON-0200, for HBV Functional Cure, at EASL 2024 (GlobeNewswire)
May-30-24 07:44AM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q (GlobeNewswire)
May-23-24 11:53AM OCEA Stock Earnings: Ocean Biomedical Reported Results for Q3 2023 (InvestorPlace) -5.16%
May-16-24 08:01AM Ocean Biomedical, Inc. (NASDAQ: OCEA) Announces Patent Allowance for Malaria Antibodies That Have Potential Capability to Protect Against Infection and Treat Severe Disease (GlobeNewswire)
Apr-24-24 04:51PM Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K (GlobeNewswire) -11.31%
Mar-28-24 01:15PM 13 Hot Stocks to Invest in According to Wall Street Analysts (Insider Monkey) -6.77%
08:01AM Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL (GlobeNewswire)
Mar-24-24 03:52PM 5 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-05-24 08:30AM Increasing Incidence of Pancreatic Cancer Leading to a $6.85 Billion Dollar Market Size for New Treatments (GlobeNewswire) +28.92%
DRMA - Dermata Therapeutics Inc - Stock Price Chart
TickerDRMA [NASD]
CompanyDermata Therapeutics Inc
CountryUSA
IndustryBiotechnology
Market Cap1.57MEPS (ttm)-32.72
P/E-EPS this Y59.63%
Forward P/E-EPS next Y71.49%
PEG-EPS past 5Y26.37%
P/S-EPS next 5Y-
P/B0.26EPS Q/Q79.29%
Dividend-Sales Q/Q-
Insider Own6.04%Inst Own0.73%
Insider Trans0.00%Inst Trans-98.32%
Short Float8.10%EarningsMay 15/a
Analyst Recom1.00Target Price10.00
Avg Volume1.17M52W Range1.29 - 23.36
Jul-17-24 09:00AM Dermata Announces Achievement of 50% Enrollment in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne (ACCESSWIRE)
May-17-24 08:30AM Dermata Therapeutics Announces Exercise of Warrants for $2.66 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules (ACCESSWIRE) -19.23%
May-15-24 10:54PM DRMA Stock Earnings: Dermata Therapeutics Misses EPS for Q1 2024 (InvestorPlace) +5.05%
04:05PM Dermata Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (ACCESSWIRE)
May-13-24 07:23AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) +5.94%
Apr-03-24 07:00AM Presenting on the Emerging Growth Conference 69 Day 2 on April 4 Register Now (GlobeNewswire)
Apr-02-24 07:00AM Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now (GlobeNewswire)
Mar-27-24 04:05PM Dermata to Present at the Emerging Growth Conference on April 3, 2024 (ACCESSWIRE)
Mar-21-24 10:53PM DRMA Stock Earnings: Dermata Therapeutics Reported Results for Q4 2023 (InvestorPlace)
04:05PM Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results (ACCESSWIRE)
FEBO - Fenbo Holdings Ltd. - Stock Price Chart
TickerFEBO [NASD]
CompanyFenbo Holdings Ltd.
CountryHong Kong
IndustryConsumer Electronics
Market Cap141.40MEPS (ttm)-0.02
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S9.30EPS next 5Y-
P/B18.37EPS Q/Q-118.18%
Dividend-Sales Q/Q4.00%
Insider Own81.36%Inst Own0.01%
Insider Trans0.00%Inst Trans-
Short Float0.53%Earnings-
Analyst Recom-Target Price-
Avg Volume28.88K52W Range4.19 - 17.68
Apr-29-24 08:00AM Fenbo Holdings Limited Reports Full Year 2023 Financial Result (GlobeNewswire) +30.24%
Jan-03-24 04:30PM Fenbo Holdings Limited Announces Appointment of Mr. Meng Derong as Co-Chairman and Independent Non-Executive Director (GlobeNewswire) +7.39%
Dec-01-23 04:12PM Fenbo Holdings Limited Announces Closing of Its Initial Public Offering (GlobeNewswire) +12.84%
Nov-29-23 05:27PM Fenbo Holdings Limited Announces Pricing of Its Initial Public Offering (GlobeNewswire)
QTTB - Q32 Bio Inc. - Stock Price Chart
TickerQTTB [NASD, RUT]
CompanyQ32 Bio Inc.
CountryUSA
IndustryBiotechnology
Market Cap432.59MEPS (ttm)-32.50
P/E-EPS this Y47.05%
Forward P/E-EPS next Y-16.99%
PEG-EPS past 5Y-0.07%
P/S1235.96EPS next 5Y-9.40%
P/B8.86EPS Q/Q29.65%
Dividend-Sales Q/Q-100.00%
Insider Own67.76%Inst Own8.46%
Insider Trans-0.17%Inst Trans-18.57%
Short Float6.83%EarningsMay 09/b
Analyst Recom1.00Target Price62.25
Avg Volume74.36K52W Range8.24 - 42.98
Jul-09-24 06:59AM Q32 Bio Announces Completion of Enrollment in the SIGNAL-AD Phase 2 Clinical Trial of Bempikibart for Atopic Dermatitis (PR Newswire) +7.89%
Jul-01-24 06:59AM Q32 Bio Joins Russell 3000 Index (PR Newswire) +5.74%
May-09-24 01:56PM QTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024 (InvestorPlace)
06:59AM Q32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update (PR Newswire)
Apr-03-24 07:00AM Q32 Bio Appoints Lee Kalowski as President & Chief Financial Officer (PR Newswire)
Mar-18-24 04:30PM Homology Medicines Declares Distribution to Common Stockholders (GlobeNewswire)
Mar-15-24 09:52PM FIXX Stock Earnings: Homology Medicines Beats EPS for Q4 2023 (InvestorPlace)
Mar-01-24 10:48AM Kuehn Law Encourages FIXX, SCTL, EVRI, and GRPH Investors to Contact Law Firm (GlobeNewswire)
Jan-27-24 12:10PM SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates EGLE, FRLN, ROVR, FIXX (GlobeNewswire)
Jan-03-24 04:08PM Homology Medicines Receives NASDAQ Notification Regarding Minimum Bid Price Deficiency (GlobeNewswire) +5.43%
HSCS - Heart Test Laboratories Inc. - Stock Price Chart
TickerHSCS [NASD]
CompanyHeart Test Laboratories Inc.
CountryUSA
IndustryMedical Devices
Market Cap3.02MEPS (ttm)-48.40
P/E-EPS this Y-
Forward P/E-EPS next Y-
PEG-EPS past 5Y-
P/S151.14EPS next 5Y-
P/B0.34EPS Q/Q80.99%
Dividend-Sales Q/Q653.85%
Insider Own16.16%Inst Own2.19%
Insider Trans0.00%Inst Trans-
Short Float13.59%EarningsMar 14/a
Analyst Recom1.00Target Price67.50
Avg Volume82.10K52W Range3.40 - 98.00
Today 09:00AM Innovation Value Institute Analysis Demonstrates HeartSciences' MyoVista wavECG Potential to Improve Cardiovascular Pathway Efficiency (GlobeNewswire) +22.13%
Jul-25-24 08:30AM HeartSciences Selected to Demonstrate MyoVista wavECG at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare (GlobeNewswire)
Jul-11-24 09:00AM HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction (GlobeNewswire) -8.60%
Jun-04-24 04:15PM HeartSciences Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire) -9.49% +7.77%
May-20-24 09:00AM HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio (GlobeNewswire) -15.64%
May-13-24 07:23AM Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday (InvestorPlace) -19.77%
Apr-24-24 09:00AM HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG (GlobeNewswire) +9.10%
Apr-02-24 04:15PM HeartSciences to Present at the LD Micro Invitational XIV Conference (GlobeNewswire) -6.09%
Mar-26-24 09:00AM HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients (GlobeNewswire)
Mar-14-24 09:54PM HSCS Stock Earnings: Heart Test Laboratories Beats EPS for Q3 2024 (InvestorPlace) +5.75%
TARS - Tarsus Pharmaceuticals Inc - Stock Price Chart
TickerTARS [NASD, RUT]
CompanyTarsus Pharmaceuticals Inc
CountryUSA
IndustryBiotechnology
Market Cap944.88MEPS (ttm)-4.77
P/E-EPS this Y20.47%
Forward P/E-EPS next Y55.40%
PEG-EPS past 5Y-132.82%
P/S22.20EPS next 5Y-
P/B3.43EPS Q/Q-15.59%
Dividend-Sales Q/Q1004.56%
Insider Own17.86%Inst Own98.63%
Insider Trans-0.58%Inst Trans1.80%
Short Float28.38%EarningsMay 08/a
Analyst Recom1.33Target Price57.62
Avg Volume655.47K52W Range12.57 - 42.50
May-29-24 05:00PM Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
1234567891011⋯20
affiliate • advertise • toggle light mode • contact • help • privacy • do not sell my data
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2024 FINVIZ.com. All Rights Reserved.